Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danoprevir IV/oral pharmacokinetics, cyclosporine interaction, and absolute bioavailability study in healthy adults
NL-OMON37643Active, not recruiting
- Sponsor
- Roche
- Start
- Jun 2012
- Modality
- Small Molecules, Peptides, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of danoprevir, ritonavir and cyclosporine in hepatitis C virus infection (4 arms), sponsored by Roche. Primary endpoints: Plasma pharmacokinetics of danoprevir and ritonavir in Part 1, Plasma pharmacokinetics of danoprevir and ritonavir in Part 2 and 2 more. Started Jun 2012; status: active, not recruiting.
02
Drugs
danoprevirritonavircyclosporine
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON37643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37643.